CDX 1307
/ Celldex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 13, 2020
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
(clinicaltrials.gov)
- P2; N=3; Terminated; Sponsor: Celldex Therapeutics; N=30 ➔ 3
Clinical • Enrollment change
1 to 1
Of
1
Go to page
1